Korean J Physiol Pharmacol.  2008 Oct;12(5):281-286. 10.4196/kjpp.2008.12.5.281.

Tyrphostin ErbB2 Inhibitors AG825 and AG879 Have Non-specific Suppressive Effects on gp130/ STAT3 Signaling

• Lee HK
• Seo IA
• Lee SH
• Seo SY
• Kim KS
• Park HT

• KMID: 1486111
• DOI: http://doi.org/10.4196/kjpp.2008.12.5.281

Abstract

Although the interaction between gp130 and the ErbB family has frequently been shown in cancer cells, the mechanism of this interaction remains unclear and controversial. In the present study, we found that specific tyrphostin inhibitors of ErbB2 (AG825 and AG879), but not ErbB1 inhibitor (AG1478), suppressed IL-6-induced tyrosine phosphorylation of STAT3 in schwannoma cells. However, biochemical evidence for transactivation of ErbB2 by IL-6 was not observed. Additionally, the inhibition of ErbB2 expression, with either a specific RNAi or transfection of an ErbB2 mutant lacking the intracellular domain did not inhibit the IL-6-induced tyrosine phosphorylation of STAT3. Thus, it seems that tyrphostins, which are known as specific inhibitors of the ErbB2 kinase, may have non-specific suppressive effects on the IL-6/STAT3 pathway.

Keyword

ErbB2 kinase; Interleukin-6; gp130; Schwannoma; STAT3; Neuregulin

MeSH Terms

Humans
Interleukin-6
Neurilemmoma
Phosphorylation
Phosphotransferases
Transcriptional Activation
Transfection
Tyrosine
Tyrphostins
Interleukin-6
Phosphotransferases
Tyrosine
Tyrphostins

Figure

• 

  Fig. 1. Specific tyrphostin ErbB2 inhibitors block IL-6-induced tyrosine phosphorylation of STAT3. (A, B) The effects of an ErbB1 inhibitor (AG1478) or ErbB2 inhibitors (AG825, AG879) on IL-6- induced tyrosine phosphorylation of STAT3 in RT4 cells were analyzed. ErbB2 inhibitors dose-dependently reduced tyrosine phosphorylation of STAT3 induced by IL-6. (C) STAT3 DNA binding activity was analyzed using a STAT3-interacting oligonucleotide conjugated to agarose beads, after 20 min of IL-6 treatment. STAT3 was immunoprecipitated and analyzed via immunoblotting, with antibodies against pSTAT3 or STAT3. (D) An ErbB1/ErbB2 dual inhibitor, GW583340, did not block IL-6-induced tyrosine phosphorylation of STAT3.

• 

  Fig. 2. Effects of ErbB1 and ErbB2 inhibitors on IL-6-induced tyrosine phosphorylation of STAT3 in primary Schwann cells. (A) The selective inhibition of IL-6-induced (20 min) tyrosine phosphorylation of STAT3 by AG825 was demonstrated in primary Schwann cells. (B) Dose-dependent curves showing the effect of AG825 on RT4 (▪) cells and primary Schwann cells (•). The intensity of IL-6- stimulated pSTAT3 band in the absence of AG825 was set as 100% of relative intensity. The curve shows that primary Schwann cells were more sensitive to AG825 than RT4 cells.

• 

  Fig. 3. IL-6 does not transactivate ErbB2 in Schwann cells. (A) Western blot analysis with anti-phospho-ErbB2 antibodies showed that IL-6 did not induce tyrosine phosphorylation of ErbB2 at tyrosines 877, 1221 or 1222, whereas NRG induced strong tyrosine phosphorylation of ErbB2 at tyrosine 877 and mild phosphorylation at tyrosines 1221 and 1222. (B) Cell lysates were subjected to immunoprecipitations using either an anti-gp130 antibody or an anti-ErbB2 antibody, and then immunoblotting was performed using an anti-phosphotyrosine antibody (4G10, pY). IL-6 did not induce tyrosine phosphorylation of ErbB2, while it did stimulate the tyrosine phosphorylation of gp130. (C) Cell lysates were subjected to immunoprecipitations using either an anti-gp130 antibody or an anti-IL-6R antibody, and then immunoblotting was performed using an antibody to ErbB2 to demonstrate interactions between gp130 and ErbB2 or between IL-6R and ErbB2. IL-6 induced an interaction between IL-6R and gp130, but did not induce an interaction between ErbB2 and gp130 or IL-6R.

• 

  Fig. 4. Specific ablation of ErbB2 function does not inhibit IL-6-induced tyrosine phosphorylation of STAT3. (A) Cells were transfected with control siRNA or ErbB2 siRNA, and IL-6-induced tyrosine phosphorylation of STAT3 was analyzed using Western blot analysis. The suppression of ErbB2 expression with a specific RNAi did not affect the IL-6-induced tyrosine phosphorylation of STAT3. (B) Cells were transfected with an ErbB2 mutant lacking the intra-cellular domain (ErbB2TR) or empty vector. Two days after transfection, cells were incubated with IL-6 for 20 min, fixed and double-immunostained with an anti-Myc antibody and an anti- pSTAT3 antibody. (C) Quantitative analysis was performed by calculating the percentage of pSTAT3-positive nuclei among Myc- positive cells. Means±S.E from three independent experiments are shown.

Reference

Badache A., Hynes NE. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res. 61:383–391. 2001.

Battle TE., Frank DA. The role of STATs in apoptosis. Curr Mol Med. 2:381–392. 2002.

Carroll SL., Miller ML., Frohnert PW., Kim SS., Corbett JA. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci. 17:1642–1659. 1997.

Chan KS., Sano S., Kiguchi K., Anders J., Komazawa N., Takeda J., DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 114:720–728. 2004.

Chen ZL., Yu WM., Strickland S. Peripheral regeneration. Annu Rev Neurosci. 30:209–233. 2007.

Cheng L., Esch FS., Marchionni MA., Mudge AW. Control of Schwann cell survival and proliferation: autocrine factors and neuregulins. Mol Cell Neurosci. 12:141–156. 1998.

Choi BH., Choi JS., Rhie DJ., Yoon SH., Min DS., Jo YH., Kim MS., Hahn SJ. Direct inhibition of the cloned Kv1.5 channel by AG-1478, a tyrosine kinase inhibitor. Am J Physiol Cell Physiol. 282:1461–1468. 2002.

Gazit A., Osherov N., Posner I., Yaish P., Poradosu E., Gilon C., Levitzki A. Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J Med Chem. 34:1896–1907. 1991.

Grant SL., Hammacher A., Douglas AM., Goss GA., Mansfield RK., Heath JK., Begley CG. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene. 21:460–474. 2002.

Grunt TW., Tomek K., Wagner R., Puckmair K., Kainz B., Rünzler D., Gaiger A., Köhler G., Zielinski CC. Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. J Cell Physiol. 211:803–815. 2007.

Huijbregts RP., Roth KA., Schmidt RE., Carroll SL. Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor beta3 in myelinating Schwann cells. J Neurosci. 23:7269–7280. 2003.

Hynes NE., Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005.

Iwamaru A., Szymanski S., Iwado E., Aoki H., Yokoyama T., Fokt I., Hess K., Conrad C., Madden T., Sawaya R., Kondo S., Priebe W., Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 26:2435–2444. 2007.

Kamimura D., Ishihara K., Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 149:1–38. 2003.

Lee HK., Seo IA., Park HK., Park HT. Identification of the basement membrane protein nidogen as a candidate ligand for tumor endothelial marker 7 in vitro and in vivo. FEBS Lett. 580:2253–2257. 2006.

Lee HK., Seo IA., Park HK., Park YM., Ahn KJ., Yoo YH., Park HT. Nidogen is a prosurvival and promigratory factor for adult Schwann cells. J Neurochem. 102:686–698. 2007.

Lee HK., Seo IA., Seo E., Seo SY., Lee HJ., Park HT. Netrin-1 induces proliferation of Schwann cells through Unc5b receptor. Biochem Biophys Res Commun. 362:1057–1062. 2007.

Ng YP. Cheung ZH, Ip NY. STAT3 as a downstream mediator of Trk signaling and functions. J Biol Chem. 281:15636–15644. 2006.

Osherov N., Gazit A., Gilon C., Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem. 268:11134–11142. 1993.

Qiu Y., Ravi L., Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature. 393:83–85. 1998.

Rahaman SO., Harbor PC., Chernova O., Barnett GH., Vogelbaum MA., Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multi-forme cells. Oncogene. 21:8404–8413. 2002.

Selander KS., Li L., Watson L., Merrell M., Dahmen H., Heinrich PC., Müller-Newen G., Harris KW. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res. 64:6924–6933. 2004.

Stonecypher MS., Byer SJ., Grizzle WE., Carroll SL. Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene. 24:5589–5605. 2005.

Tsai CM., Levitzki A., Wu LH., Chang KT., Cheng CC., Gazit A., Perng RP. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185 (neu) expressing non-small cell lung cancer cells. Cancer Res. 56:1068–1074. 1996.

Xie Y., Tisi MA., Yeo TT., Longo FM. Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects. J Biol Chem. 275:29868–29874. 2000.